Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 5.06
OCRX's Cash to Debt is ranked lower than
61% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. OCRX: 5.06 )
Ranked among companies with meaningful Cash to Debt only.
OCRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.68  Med: 9999.00 Max: No Debt
Current: 5.06
Equity to Asset 0.74
OCRX's Equity to Asset is ranked higher than
58% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OCRX: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
OCRX' s Equity to Asset Range Over the Past 10 Years
Min: -1.09  Med: 0.66 Max: 0.96
Current: 0.74
-1.09
0.96
F-Score: 2
Z-Score: -1.54
M-Score: -3.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -18038.13
OCRX's Operating margin (%) is ranked lower than
95% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. OCRX: -18038.13 )
Ranked among companies with meaningful Operating margin (%) only.
OCRX' s Operating margin (%) Range Over the Past 10 Years
Min: -18034.12  Med: -3770.24 Max: -63.42
Current: -18038.13
-18034.12
-63.42
Net-margin (%) -17971.22
OCRX's Net-margin (%) is ranked lower than
95% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. OCRX: -17971.22 )
Ranked among companies with meaningful Net-margin (%) only.
OCRX' s Net-margin (%) Range Over the Past 10 Years
Min: -20604.71  Med: -3822.91 Max: -85.5
Current: -17971.22
-20604.71
-85.5
ROE (%) -55.43
OCRX's ROE (%) is ranked lower than
65% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. OCRX: -55.43 )
Ranked among companies with meaningful ROE (%) only.
OCRX' s ROE (%) Range Over the Past 10 Years
Min: -236.08  Med: -142.63 Max: -49.17
Current: -55.43
-236.08
-49.17
ROA (%) -49.90
OCRX's ROA (%) is ranked lower than
68% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. OCRX: -49.90 )
Ranked among companies with meaningful ROA (%) only.
OCRX' s ROA (%) Range Over the Past 10 Years
Min: -87.61  Med: -54.63 Max: -15.31
Current: -49.9
-87.61
-15.31
ROC (Joel Greenblatt) (%) -37132.05
OCRX's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. OCRX: -37132.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46351.52  Med: -2161.38 Max: -526.49
Current: -37132.05
-46351.52
-526.49
Revenue Growth (3Y)(%) -85.60
OCRX's Revenue Growth (3Y)(%) is ranked lower than
91% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. OCRX: -85.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OCRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -48.80 Max: -85.6
Current: -85.6
EBITDA Growth (3Y)(%) -53.20
OCRX's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. OCRX: -53.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -41.10 Max: -53.2
Current: -53.2
EPS Growth (3Y)(%) -54.20
OCRX's EPS Growth (3Y)(%) is ranked lower than
94% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. OCRX: -54.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -42.05 Max: -54.2
Current: -54.2
» OCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

OCRX Guru Trades in Q4 2014

Jim Simons 12,549 sh (-67.11%)
» More
Q1 2015

OCRX Guru Trades in Q1 2015

Jim Simons Sold Out
» More
Q2 2015

OCRX Guru Trades in Q2 2015

Jim Simons 35,200 sh (New)
» More
Q3 2015

OCRX Guru Trades in Q3 2015

Jim Simons 58,200 sh (+65.34%)
» More
» Details

Insider Trades

Latest Guru Trades with OCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.57
OCRX's P/B is ranked higher than
75% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. OCRX: 1.57 )
Ranked among companies with meaningful P/B only.
OCRX' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 2.03 Max: 10.49
Current: 1.57
0.98
10.49
EV-to-EBIT -0.76
OCRX's EV-to-EBIT is ranked lower than
99.99% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. OCRX: -0.76 )
Ranked among companies with meaningful EV-to-EBIT only.
OCRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.2  Med: -1.35 Max: 1.1
Current: -0.76
-19.2
1.1
EV-to-EBITDA -0.77
OCRX's EV-to-EBITDA is ranked lower than
99.99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. OCRX: -0.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
OCRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.4  Med: -1.35 Max: 1.1
Current: -0.77
-19.4
1.1
Current Ratio 13.75
OCRX's Current Ratio is ranked higher than
83% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. OCRX: 13.75 )
Ranked among companies with meaningful Current Ratio only.
OCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 5.90 Max: 21.99
Current: 13.75
0.62
21.99
Quick Ratio 13.75
OCRX's Quick Ratio is ranked higher than
84% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. OCRX: 13.75 )
Ranked among companies with meaningful Quick Ratio only.
OCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 5.90 Max: 21.99
Current: 13.75
0.62
21.99
Days Sales Outstanding 91.91
OCRX's Days Sales Outstanding is ranked lower than
67% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. OCRX: 91.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.55  Med: 114.91 Max: 399.35
Current: 91.91
23.55
399.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.64
OCRX's Price/Net Cash is ranked higher than
86% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. OCRX: 1.64 )
Ranked among companies with meaningful Price/Net Cash only.
OCRX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.54  Med: 3.10 Max: 10.42
Current: 1.64
1.54
10.42
Price/Net Current Asset Value 1.61
OCRX's Price/Net Current Asset Value is ranked higher than
87% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. OCRX: 1.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OCRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.35  Med: 2.80 Max: 8.97
Current: 1.61
1.35
8.97
Price/Tangible Book 1.60
OCRX's Price/Tangible Book is ranked higher than
83% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. OCRX: 1.60 )
Ranked among companies with meaningful Price/Tangible Book only.
OCRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.24  Med: 2.69 Max: 7.99
Current: 1.6
1.24
7.99
Earnings Yield (Greenblatt) (%) -131.60
OCRX's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OCRX: -131.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 94.3  Med: 119.80 Max: 3732.6
Current: -131.6
94.3
3732.6

More Statistics

Revenue(Mil) $0
EPS $ -1.26
Beta2.63
Short Percentage of Float1.14%
52-Week Range $2.00 - 7.16
Shares Outstanding(Mil)20.50

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:6TY1.Germany,
Ocera Therapeutics Inc was incorporated in Delaware on December 20, 2004. The Company is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of OCR-002 for the treatment of hepatic encephalopathy or HE. OCR-002 is a novel molecule, ornithine phenylacetate, which functions as an ammonia scavenger. In pre-clinical studies, OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia, brain ammonia and intracranial pressure in a second animal model of acute liver failure. OCR-002 has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperammonemia and resultant HE in patients with acute liver failure and acute-on-chronic liver disease. OCR-002 has also been granted orphan drug designation in the European Union for the treatment of acute liver failure. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat HE. The Company is subject to federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for OCRX

Headlines

Articles On GuruFocus.com
Three Insider Buys at 52-Week Lows Jul 22 2014 
Weekly CEO Buys Highlight: OPK, QTET, MIC, FAST, OCRX Jul 21 2014 
Top 3 Insider Buys of the Week Jul 19 2013 

More From Other Websites
Ocera to Present at the 18th Annual BIO CEO & Investor Conference Feb 02 2016
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jan 08 2016
Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in... Jan 08 2016
Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in... Jan 08 2016
Ocera Appoints Dr. Stan Bukofzer as Chief Medical Officer Jan 07 2016
Ocera Appoints Dr. Stan Bukofzer as Chief Medical Officer Jan 07 2016
A Refreshing Outlook -- Comprehensive Research on AU Optronics, Ocera Therapeutics, Solar3D and... Dec 22 2015
Ocera Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 18 2015
OCERA THERAPEUTICS, INC. Financials Dec 08 2015
Are Hedge Funds Losing Interest In Ocera Therapeutics Inc (OCRX)? Nov 25 2015
Ocera (OCRX) Stock Rises on Positive Drug Trial Results Nov 17 2015
Ocera Therapeutics Rises on Positive Phase 1 Results Nov 17 2015
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 16 2015
Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of... Nov 16 2015
Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of... Nov 16 2015
Ocera to Present at Stifel 2015 Healthcare Conference Nov 09 2015
OCERA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 05 2015
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 04 2015
Ocera Therapeutics Reports Third Quarter 2015 Financial Results Nov 04 2015
Ocera Therapeutics, Inc. – Value Analysis (NASDAQ:OCRX) : October 30, 2015 Oct 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK